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325dilated by PTPA. Meanwhile, lesion type B is
moderately difficult to identify by angiography, and
OCT revealed a honeycomb-like structure. Lesion
type C is a representative lesion that is difficult to
identify by angiography. OCT revealed a lotus root–
like structure in the pulmonary artery in this lesion
before PTPA, and impaired flow was confirmed by
pressure ratio. Blood flow could pass through
some of the spaces in the lotus root–like structure,
but each of these flow spaces was significantly
narrowed, which may explain why this lesion was
difficult to identify by angiography and had a
significantly reduced pressure ratio. OCT after
PTPA demonstrated that the lotus root–like structure
was destroyed by balloon dilation and crushed
toward the vessel wall, accompanied by significant
improvement of pressure ratio (>0.8), demonstrating
that the lesions with lotus root–like structures can be
easily dilated by PTPA. Lesion type D, located within
a pulmonary artery that has unimpaired blood flow
and with a pressure ratio that was detected by
pressure wire, was also within the normal range.
However, OCT demonstrated a lotus root–like
structure within this vessel, with possible organized
thrombus adherence to the vessel wall. The main
space through which blood flow passed was not
significantly narrowed, which may explain why
this vessel had a lotus root–like structure but no
impaired flow. Interestingly, OCT in lesion type D
demonstrated that normal angiographic findings and
a preserved value of pressure ratio do not necessarily
ensure normal structure of vessels in CTEPH. These
findings suggested that the lotus root–like structure
could be seen in 2 cases (i.e., lesions with or without
impaired flow) but both are difficult to identify by
angiography.
PTPA has recently been developed and needs
further improvement. The findings in this report
suggest that OCT is a useful tool to demonstrate the
morphological features of lesions. In particular, OCT
is useful to detect target lesions that are difficult to
identify by angiography. A combined approach, using
angiography as a subjective tool to evaluate flow
grade, a pressure wire to provide an objective value
of flow impairment, and OCT as a useful tool to
demonstrate the concrete morphological features of a
lesion, may enable more appropriate judgment
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and Wild-Type Transthyretin-Related
Cardiac AmyloidosisDegenerative aortic stenosis (AS) is a growing cause of
heart failure and death in the elderly. The majority of
patients with symptomatic AS are currently treated
with surgical or transcatheter aortic valve replace-
ment (TAVR). It was recently suggested (1) that a
share of the sometimes lethal complications arising
during and after aortic valve replacement are to be
attributed to coexistent cardiac amyloidosis. In an
autopsy series of patients who had undergone
TAVR, Nietlispach et al. (2) found varying degrees of
ventricular myocardium amyloid infiltration in
approximately one-third of cases. The etiology of
amyloidosis was not defined, but considering
patient age and clinical profile, it is plausible
that these patients had wild-type transthyretin
FIGURE 1 Patient With Aortic Stenosis and Wild-Type TTR–Related Amyloidosis
(A and B) Echocardiogram showing “red flags” for cardiac amyloidosis: ventricular
myocardium granular sparkling, atrioventricular valve thickening, and mild pericardial
effusion. (C). Electrocardiogram: typical signs of severe aortic stenosis (left ventricular
hypertrophy) are absent. (D) Technetium–99m-3,3-diphosphono-1,2 propanodicarboxylic
acid scintigraphy showing strong myocardial tracer uptake. (E and F) Endomyocardial
biopsy with TTR-related amyloid infiltration. (E) Hematoxylin-eosin, Congo red staining.
(F) Immunohistochemistry with anti-TTR antibodies. TTR ¼ transthyretin.
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326(TTR)–related amyloidosis (wt-ATTR). Indeed,
degenerative AS and wt-ATTR share a common
demographic and clinical profile. Data from
postmortem studies in unselected subjects indicate
a prevalence of cardiac amyloidosis of 22% to 25% in
subjects older than 80 years of age (3).
TTR-related cardiac amyloidosis can currently be
accurately identified by scintigraphy with bone-
seeking tracers (4). A recent study with technetium–
99m-3,3-diphosphono-1,2 propanodicarboxylic acid
(99mTc-DPD) scintigraphy in 12,400 subjects found a
prevalence of strong, unexpected myocardial tracer
uptake, suggestive of cardiac amyloidosis, in w1.4%
of subjects older than 80 years of age (5).
To clinically investigate the coexistence of cardiac
amyloidosis in elderly patients with AS referred for
aortic valve replacement (surgical or transcatheter),
we prospectively evaluated with 99mTc-DPD scintig-
raphy all patients with degenerative AS and 1 or
more of the following echocardiographic “red flags”:
increased thickness of atrioventricular valves, intera-
trial septum or right ventricular free wall, pericardial
effusion, and myocardial granular sparkling.
Of the 43 patients referredwithAS (betweenOctober
2014 and January 2015), 5 had echocardiographic“red flags” and underwent 99mTc-DPD scintigraphy
before a final decision regarding treatment was made.
The scan showed strong myocardial uptake in all
patients. All then underwent endomyocardial biopsy,
which consistently demonstrated TTR-related amy-
loid infiltration. Genetic analysis excluded TTR
gene mutations, and wt-ATTR was diagnosed in all
5 patients.
Of the 5 patients with wt-ATTR, only 1 was female
(median age 84 years; range 76 to 90 years), and all
had advanced heart failure (New York Heart Associ-
ation functional class III/IV). Interestingly, 3 had a
history of carpal tunnel syndrome (bilateral in 2 pa-
tients). All had marked symmetrical left ventricular
(LV) hypertrophy (median wall thickness, 18 mm;
range 16 to 21 mm) with a calculated aortic valve
area #0.6 cm2/m2. In 4 of 5 patients, a low flow–low
gradient condition was present (with reduced LV
ejection fraction in 2 patients). Remarkably, all
echocardiographic “red flags” were present in 3 of 5
patients, and longitudinal function was depressed in
all patients. A disproportion between echocardio-
graphic LV “hypertrophy” and normal QRS voltages
was present in 4 patients (only 1 satisfied electro-
cardiographic criteria for LV hypertrophy). All pa-
tients underwent balloon aortic valvuloplasty with a
“bridge to decision” strategy and are currently un-
dergoing a clinical follow-up. Figure 1 summarizes the
instrumental findings of a typical case.
This small preliminary study found that the coex-
istence of degenerative AS and wt-ATTR (a poten-
tially dangerous condition in patients undergoing
aortic valve replacement) can be suspected on the
basis of clinical and echocardiographic elements and
can be effectively diagnosed by 99mTc-DPD scintig-
raphy. The study cannot provide data on disease
prevalence and test sensitivity but suggests that
particular attention should be paid to patients with
echocardiographic signs of myocardial infiltration
and/or a mismatch between LV wall thickness and
QRS voltages and/or low flow–low gradient and
depressed longitudinal myocardial function. Larger
prospective studies are needed to establish in which
patients with AS to search for cardiac amyloidosis as
well as how to use this information in the treatment
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2014;7:531–2.How to Distinguish Between Myocarditis
and Sarcoidosis Based on CMR ImagingI read with great interest the manuscript “Late Gado-
linium Enhancement Among Survivors of Sudden
Cardiac Arrest” (1). This paper offers the best available
guidance on the management of this complex group
of patients, which we recently utilized in the
management of one of the patients admitted to our
hospital. As someone who performs cardiac magnetic
resonance imaging, I am often confronted by the
inability to distinguish between active myocarditis
and cardiac sarcoidosis, especially when theventricles do not exhibit gross structural abnor-
malities. I find the delayed gadolinium enhancement
pattern alone insufficient in distinguishing between
these conditions unless extra-cardiac sarcoidosis is
manifest.
Perhaps this distinction is moot since late gadolin-
ium enhancement turns out to be the single best pre-
dictor of future appropriate implantable cardioverter-
defibrillator therapy. On the other hand, this may be
important because treatment for sarcoidosis may be
available. Additionally, a clear definition of the
mechanisms/disease that leads to sudden cardiac
death is important from the epidemiologic point of
view. Therefore, it would be helpful for the in-
vestigators to highlight the methods utilized to
distinguish between these conditions.Ashish Aneja, MBBS*
*Cardiovascular Medicine
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Sarcoidosis consists of both an active, inflamma-
tory phase as well as a chronic phase, in which
scarring and fibrosis are present. Although the
cardiac magnetic resonance (CMR) features of the
2 conditions overlap especially during the acute
phase, there are some suggestive features that help
differentiate the two (2,3). The following features
are typically seen in cardiac sarcoidosis (2,3):
1. Late gadolinium enhancement (LGE) in cardiac
sarcoidosis often involves more than one segment,
in a basal distribution, and often involves the
septum.
